| Table of Contents: | ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 8
Bristol-Myers Squibb: PharmaVitae forecasts at a glance 9
Strategic insight 10
Plavix exposure drives BMS over 2012 patent cliff 10
BMS has the second fastest expiry decline within Big Pharma 13
BMS will focus on areas of high unmet need to mitigate the decline of its CV portfolio 14
BMS builds Big Pharma collaborations 16
Pfizer collaboration for apixaban 17
Antidiabetic collaboration with AstraZeneca 18
BMS fast evolving into a fully-fledged biopharmaceutical player 19
Productivity transformation initiative expected to lower operating costs 20
Increasingly profitable business model makes BMS an attractive M&A target 20
SWOT analysis 22
Strengths 22
Weaknesses 24
Opportunities 24
Threats 25
Table of Contents 26
Table of figures 28
Chapter 3 Quarterly news update 29
Product developments 29
Deals and alliances 31
Company announcements 32
Future product milestones 33
Chapter 4 Company introduction 34
Key findings 34
Background 35
Key corporate developments 35
Bristol-Myers 35
Squibb 35
Bristol-Myers Squibb 35
M&A history 36
Medarex 36
Kosan Biosciences 37
Adnexus Therapeutics 37
Acordis Speciality Fibres 37
DuPont Pharmaceuticals 37
Mead Johnson 38
ConvaTec 38
Medical Imaging 39
Consumer Medicines 39
Oncology Therapeutics Network 39
Corporate restructuring to focus on pharma 39
Chapter 5 Company sales 41
Key findings 41
Prescription pharmaceutical sales and growth rate analysis, 2002-14 42
Historical analysis 43
Forecast analysis 44
Product analysis 45
Product analysis, 2002-08 46
Growth drivers 47
Growth resistors 48
Product analysis, 2008-14 50
Growth drivers 52
Growth resistors 53
Therapy area analysis 54
Geographic analysis 56
Launch/core/expiry analysis 58
Explanation of launch/core/expiry analysis 58
Launch analysis, 2008-14 59
Core analysis, 2008-14 60
Expiry analysis, 2008-14 61
Launch/core/expiry configuration, 2008-14 62
Molecule type analysis 63
Externalization analysis 65
Chapter 6 Company financials 67
Key findings 67
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 68
Financial statements, 2001-07 70
Operating costs and profit analysis 70
Operating costs and profit analysis, 2002-08 71
Operating cost ratio and profit margin analysis, 2002-08 72
Operating cost ratio and profit margin analysis, 2008-14 73
Operating costs and profit analysis, 2008-14 74
Chapter 7 Key products and competitors 75
Key findings 75
Overview 76
Infectious diseases 77
Reyataz 77
Overview 77
Sales forecast 79
Kaletra set precedent for all future protease inhibitors 79
Reyataz overtakes Kaletra as the new class leading protease inhibitor 80
Competition intensifies following arrival of Prezista 80
Sustiva franchise 82
Overview 82
Sales forecast 83
Sustiva sales lifted by bulk use in market-leading Atripla 83
Atripla's dominance threatened by drugs offering better tolerability 84
Sustiva patent expiry to shift market share back to Truvada 84
Baraclude 85
Overview 85
Sales forecast 86
A single product hepatitis B franchise 86
Oncology 87
Erbitux 87
Overview 87
Sales forecast 88
Lucrative oncology license for North American market 88
Additional approvals key to expanded market potential 89
Sprycel 90
Overview 90
Sales forecast 91
Further approvals will help to reinforce market position 91
BMS pursues indication expansion in order to grow Sprycel commercial potential 92
Ixempra 93
Overview 93
Sales forecast 94
Central nervous system 96
Abilify 96
Overview 96
Sales forecast 98
Extended Abilify co-promotion terms reinforces BMS's position in psychiatric market 98
Extension to Abilify co-promotion agreement reinforces BMS's position in psychiatric market 99
Intramuscular version of Abilify is unlikely to challenge Zyprexa IM 99
Potential market-leading oral antipsychotic after genericization of class 100
Immunology & inflammation 101
Orencia 101
Overview 101
Sales forecast 103
Uptake of novel autoimmune disorder biologic increases with experience and confidence 103
Cardiovascular 105
Plavix 105
Overview 106
Sales forecast 107
Market-leading antithrombotic 107
Patent protection secured out to 2011 108
Endocrine, metabolic & genetic disorders 110
Onglyza 110
Overview 110
Sales forecast 111
Chapter 8 Appendix 113
R&D pipeline 113
References 115
Datamonitor reports 115
Abbreviations 115
Exchange rates 117
About Datamonitor 118
About Datamonitor Healthcare 118
Datamonitor consulting 118
Disclaimer 120
List of Tables
Table 1: Bristol-Myers Squibb - PharmaVitae forecasts at a glance 9
Table 2: Bristol-Myers Squibb's exposure to Plavix sales ($m), 2008-14 12
Table 3: Expiry sales across Big Pharma ($m), 2008 & 2014 13
Table 4: Key Brands within Bristol-Myers Squibb's prescription portfolio 14
Table 5: Bristol-Myers Squibb key product developments, 2009 29
Table 6: Bristol-Myers Squibb deals and alliances, 2009 31
Table 7: Bristol-Myers Squibb company announcements, 2009 32
Table 8: BMS future product milestones, 2009-11 33
Table 9: Bristol-Myers Squibb product portfolio overview ($m), 2002-08 46
Table 10: Bristol-Myers Squibb product portfolio overview ($m), 2008-14 50
Table 11: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2008-14 55
Table 12: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2008-14 57
Table 13: Bristol-Myers Squibb launch portfolio overview ($m), 2008-14 59
Table 14: Bristol-Myers Squibb core portfolio overview ($m), 2008-14 60
Table 15: Bristol-Myers Squibb expiry portfolio overview ($m), 2008-14 61
Table 16: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2008-14 64
Table 17: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2008-14 66
Table 18: Total Bristol-Myers Squibb sales by business unit ($m), 2002-08 68
Table 19: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2002-08 71
Table 20: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2002-08 72
Table 21: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2008-14 73
Table 22: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2008-14 74
Table 23: Key products overview 76
Table 24: Reyataz: overview 77
Table 25: Reyataz: sales forecast ($m), 2008-14 79
Table 26: Sustiva franchise: overview 82
Table 27: Sustiva franchise: sales forecast ($m), 2008-14 83
Table 28: Baraclude: overview 85
Table 29: Baraclude: sales forecast ($m), 2008-14 86
Table 30: Erbitux: overview 87
Table 31: Erbitux: sales forecast ($m), 2008-14 88
Table 32: Sprycel: overview 90
Table 33: Sprycel: sales forecast ($m), 2008-14 91
Table 34: Ixempra: overview 93
Table 35: Ixempra: sales forecast ($m), 2008-14 94
Table 36: Abilify: overview 96
Table 37: Abilify: sales |
